ESTUTC-5 New YorkLog in Sign up

CGEM
Cullinan Therapeutics, Inc. Common Stock
stockNASDAQ

Market OpenNov 10, 2026 1:44:40 PM EST

11.13USD-5.115%(-0.60)387,851

Pre-marketNov 10, 2026 9:25:30 AM EST

11.62USD-0.938%(-0.11)

11.10Bid11.16Ask0.06Spread

CGEM News

Day breaks

10:02 AM ESTCullinan Therapeutics (CGEM) Reports Q3 Net Loss of $49.4M Amid Trial Delays ·

GuruFocus

09:41 AM ESTCullinan Therapeutics reports Q3 results ·

Seeking Alpha

09:30 AM ESTCullinan Therapeutics Reports Q3 2026 Net Loss of $49.4 Million and GAAP EPS of -$0. ... ·

GuruFocus

07:00 AM ESTCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results ·

GlobeNewswire Inc.

10:00 AM ESTCullinan Therapeutics to Participate in Upcoming Investor Conferences ·

GlobeNewswire Inc.

03:26 PM ESTCullinan Therapeutics (CGEM) Reports Positive Phase 1b/2a Data on Velinotamig for Refractory SLE ·

GuruFocus

10:30 AM ESTVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 ·

GlobeNewswire Inc.

02:25 PM ESTCullinan Therapeutics (CGEM) Shares Drop 21% After Early Data Release on CLN-049 Ahead of ASH 2026 ·

GuruFocus

01:12 PM ESTCullinan Therapeutics earnings up next as zipalertinib nears finish line ·

Investing.com

09:14 AM ESTCullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting ·

GlobeNewswire Inc.

07:00 AM EDTCullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA ·

GlobeNewswire Inc.

07:30 PM EDTNew Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program ·

GlobeNewswire Inc.

02:11 PM EDTCullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances ·

Investing.com

07:00 AM EDTCullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio ·

GlobeNewswire Inc.

03:41 AM EDTMarket Movers | Winners: QNC, EGHT, FSLY | Losers: CGEM, ALKT, RAPP ·

Trefis

12:49 PM EDTThe Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data ·

Investor's Business Daily

12:00 PM EDTCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum ·

GlobeNewswire Inc.

10:20 AM EDT10 small-cap healthcare stocks with the strongest momentum grades ·

Seeking Alpha

04:44 AM EDTTaiho, Cullinan report improved PFS in Phase III NSCLC trial ·

Clinical Trials Arena

01:00 PM EDTCullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer ·

GlobeNewswire Inc.